27 Jan 2022

Ted Kloosterman joins ENPICOM as Head of Commerce

Industry veteran to drive ENPICOM’s global marketing and market expansion

We are pleased to announce the appointment of Ted Kloosterman as our Head of Commerce. Ted most recently served Agendia NV as Vice President Commercial EMEA where his role was to drive sales in Europe through heading sales and marketing activities and distributor collaborations with the European sales and marketing teams. Next to that, he was also responsible for pursuing European reimbursements (HTA & HCI’s), governmental lobby activities, and business development for the NGS-version of early-stage breast cancer genomic tests.

Ted brings 25 years of experience in the Pharmaceutical and Diagnostics Industry, in Medical, Marketing, and Management functions in both national (Dutch) and international roles. At ENPICOM, he will be heading our commercial activities to further streamline our sales efforts and strengthen our client portfolio.

I was given the opportunity to have a close look at the ENPICOM activities in the last quarter of 2021 and am very impressed by all the antibody discovery options our IGX Platform provides, the ongoing marketing achievements made, and the fantastic atmosphere in the team! It is a great challenge for me to be on this high-tech side of the early discovery of new antibody-based drugs after so many years of supplying them to the treating physicians and their patients in need. I am very excited to be joining the ‘ENPICOM-family’ at this thrilling phase of the company.”

Ted was trained as a Medical Biologist, did his PhD on immunology research of bone marrow transplantation for leukemias, and worked as a post-doc on the ‘ancestors’ of the currently new CAR-T-cell treatments offering curation to patients with some types of cancer who would otherwise succumb to their disease. He started his career in the pharmaceutical industry in 1996 as a CRA in BMS, followed by medical and product management in Roche, where he was at the cradle of the first monoclonal antibody treatment in hematology (MabThera® (rituximab)), being the oncology brand manager in Schering AG, marketing director in Celgene’s European HQ, co-founder of his consulting agency, European brand lead in InterMune, and chief scientific officer in myTomorrows before he joined Agendia in 2018.


Meet our growing team